These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 75118)
1. Immunoenhancing agents in prevention and treatment of influenza and other viral respiratory infections. Ganguly R; Khakoo R; Spencer JC; Waldman RH Dev Biol Stand; 1977 Jun 1-3; 39():363-72. PubMed ID: 75118 [No Abstract] [Full Text] [Related]
2. Effect of immunostimulating agents on viral infections. Zerial A; Werner GH Acta Microbiol Acad Sci Hung; 1981; 28(3):325-37. PubMed ID: 6171144 [No Abstract] [Full Text] [Related]
3. [Prevention of some respiratory virus diseases with aerosols. II. Effectiveness of interferon and vaccine in influenzal infection]. Sărăţeanu D; Babes VT; Demetrescu R; Danielescu G Stud Cercet Inframicrobiol; 1967; 18(6):433-9. PubMed ID: 5590424 [No Abstract] [Full Text] [Related]
4. Immunostimulation: synthetic and biological modulators of immunity. Fudenberg HH; Whitten HD Annu Rev Pharmacol Toxicol; 1984; 24():147-74. PubMed ID: 6203479 [No Abstract] [Full Text] [Related]
6. Immunization against respiratory virus infections. Hobson D Mod Trends Immunol; 1967; 2():53-85. PubMed ID: 4298139 [No Abstract] [Full Text] [Related]
7. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167 [TBL] [Abstract][Full Text] [Related]
8. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Ninomiya A; Imai M; Tashiro M; Odagiri T Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015 [TBL] [Abstract][Full Text] [Related]
9. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice. Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802 [TBL] [Abstract][Full Text] [Related]
10. A one-size-fits-all flu vaccine? Kaiser J Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732 [No Abstract] [Full Text] [Related]
11. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice. Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814 [TBL] [Abstract][Full Text] [Related]
12. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689 [TBL] [Abstract][Full Text] [Related]
13. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208 [TBL] [Abstract][Full Text] [Related]
14. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633 [TBL] [Abstract][Full Text] [Related]
15. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660 [TBL] [Abstract][Full Text] [Related]
16. [Stimulation of influenza antibody formation following immunization with the use of ascitic tumor]. Rukavishnikova GE; Alekseeva AK Biull Eksp Biol Med; 1975 Feb; 79(2):80-4. PubMed ID: 1093578 [No Abstract] [Full Text] [Related]
17. [Influenza vaccination: reinforcement of its effectiveness by combination with an immunostimulant]. German A; Fattal-German M; Quero AM; Bizzini B Bull Acad Natl Med; 1988 Mar; 172(3):467-74. PubMed ID: 3048551 [No Abstract] [Full Text] [Related]
18. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780 [TBL] [Abstract][Full Text] [Related]
19. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Hovden AO; Cox RJ; Madhun A; Haaheim LR Scand J Immunol; 2005 Oct; 62(4):342-52. PubMed ID: 16253121 [TBL] [Abstract][Full Text] [Related]
20. [The prevention of influenza and other acute respiratory infections among the troops]. Brazhnik NP; Shevtsov VA Voen Med Zh; 1999 Dec; 320(12):16-9. PubMed ID: 10732477 [No Abstract] [Full Text] [Related] [Next] [New Search]